Literature DB >> 8782088

Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells.

A G Aprikian1, K Han, S Chevalier, M Bazinet, J Viallet.   

Abstract

Bombesin and gastrin-releasing peptide (GRP) are potent neuropeptides expressed by prostate cancer neuroendocrine cells and are related to the progression of this malignancy. This study characterizes bombesin receptors in human prostate cancer cell lines (PC-3, DU-145, LNCaP) and assesses the in vitro effect of bombesin on signal transduction and cell proliferation. [125I]Tyr4-bombesin binding assays (37 degrees C) and Scatchard analyses revealed the presence of a single class of high-affinity receptors with similar Kd values (1.5, 1.1 and 3.6 x 10(-10) M in PC-3, DU-145 and LNCaP cells respectively) but with significant differences in the number of binding sites per cell (47.6, 1.5 and 0.1 x 10(3) in PC-3, DU-145 and LNCaP cells respectively). Molecular characterization of the binding sites performed in PC-3 cells by cross-linking experiments and SDS/PAGE revealed a single radioactive band of 85 kDa. To determine which of the three known bombesin receptor subtypes (GRP receptor (GRP-R), neuromedin B receptor, bombesin receptor subtype-3) were expressed in the cell lines, reverse transcription/PCR analysis of cellular RNA followed by hybridization with receptor-specific cDNA was performed. This revealed the presence of GRP-R transcript in all cell lines, while neither of the other two receptor transcripts were expressed. When intracellular calcium mobilization was measured by Fura-2/AM cell labeling and spectrofluorometric monitoring, bombesin (100 nM) induced rapid calcium mobilization in both PC-3 (> 200% of baseline) and DU-145 (> 100% of baseline) cells, but not in LNCaP cells. However, as measured by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay and [3H]thymidine incorporation, no growth modulation was observed with bombesin or bombesin receptor antagonist at various concentrations (0-500 nM). Our data indicate that bombesin is a potent inducer of signal transduction via GRP-R receptors in androgen-insensitive PC-3 and DU-145 prostate cancer cells. This suggests that the bombesin/GRP family of neuropeptides may play a regulatory role in the biology of androgen-independent prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8782088     DOI: 10.1677/jme.0.0160297

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  13 in total

1.  A high-affinity, high-stability photoacoustic agent for imaging gastrin-releasing peptide receptor in prostate cancer.

Authors:  Jelena Levi; Ataya Sathirachinda; Sanjiv S Gambhir
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

2.  Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.

Authors:  L F Lee; J Guan; Y Qiu; H J Kung
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

3.  Gastrin-releasing peptide expression and its effect on the calcification of developing mouse incisor.

Authors:  Dong-Joon Lee; Chengri Jin; Eun-Jung Kim; Jong-Min Lee; Han-Sung Jung
Journal:  Histochem Cell Biol       Date:  2015-07-01       Impact factor: 4.304

4.  Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model.

Authors:  J Jongsma; M H Oomen; M A Noordzij; W M Van Weerden; G J Martens; T H van der Kwast; F H Schröder; G J van Steenbrugge
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

5.  Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours.

Authors:  Rosalba Mansi; Xuejuan Wang; Flavio Forrer; Beatrice Waser; Renzo Cescato; Keith Graham; Sandra Borkowski; Jean Claude Reubi; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-18       Impact factor: 9.236

6.  Intravital imaging of human prostate cancer using viral nanoparticles targeted to gastrin-releasing Peptide receptors.

Authors:  Nicole F Steinmetz; Amber L Ablack; Jennifer L Hickey; Jailal Ablack; Bhavik Manocha; Joe S Mymryk; Leonard G Luyt; John D Lewis
Journal:  Small       Date:  2011-04-26       Impact factor: 13.281

7.  Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours.

Authors:  M de Visser; H F Bernard; J L Erion; M A Schmidt; A Srinivasan; B Waser; J C Reubi; E P Krenning; M de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-08       Impact factor: 9.236

8.  Transcriptional activation of the human gastrin-releasing peptide receptor gene in gastrointestinal and prostatic epithelial cancer cells.

Authors:  Xiangping Qu; Dongmei Xiao; H Christian Weber
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

9.  Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.

Authors:  Joy C Yang; Joon-ha Ok; J Erik Busby; Alexander D Borowsky; Hsing-Jien Kung; Christopher P Evans
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

10.  Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells.

Authors:  Anna Patrikidou; Panagiotis J Vlachostergios; Ioannis A Voutsadakis; Eleana Hatzidaki; Rosalia-Maria Valeri; Chariklia Destouni; Effie Apostolou; Christos N Papandreou
Journal:  Cancer Cell Int       Date:  2012-06-20       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.